Olejnik P, Roszkowska Z, Adamus S, Kasarełło K. Multiple sclerosis: a narrative overview of current pharmacotherapies and emerging treatment prospects. Pharmacol Rep. 2024;76:926–43.

Article  PubMed  PubMed Central  Google Scholar 

Polman CH, Bertolotto A, Deisenhammer F, Giovannoni G, Hartung H-P, Hemmer B, et al. Recommendations for clinical use of data on neutralising antibodies to interferon-beta therapy in multiple sclerosis. Lancet Neurol. 2010;9:740–50.

Article  CAS  PubMed  Google Scholar 

Brinkmann V. FTY720 (fingolimod) in multiple sclerosis: therapeutic effects in the immune and the central nervous system. Br J Pharmacol. 2009;158:1173–82.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Martinelli Boneschi F, Vacchi L, Rovaris M, Capra R, Comi G. Mitoxantrone for multiple sclerosis. Cochrane Database Syst Rev. 2013;2013:CD002127.

Hartung H-P, Gonsette R, König N, Kwiecinski H, Guseo A, Morrissey SP, et al. Mitoxantrone in progressive multiple sclerosis: a placebo-controlled, double-blind, randomised, multicentre trial. Lancet. 2002;360:2018–25.

Article  PubMed  Google Scholar 

Bar-Or A, Calkwood JC, Chognot C, Evershed J, Fox EJ, Herman A, et al. Effect of ocrelizumab on vaccine responses in patients with multiple sclerosis: the VELOCE study. Neurology. 2020;95:e1999-2008.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hauser SL, Waubant E, Arnold DL, Vollmer T, Antel J, Fox RJ, et al. B-cell depletion with rituximab in relapsing-remitting multiple sclerosis. N Engl J Med. 2008;358:676–88.

Article  CAS  PubMed  Google Scholar 

Polman CH, O’Connor PW, Havrdova E, Hutchinson M, Kappos L, Miller DH, et al. A randomized, placebo-controlled trial of natalizumab for relapsing multiple sclerosis. N Engl J Med. 2006;354:899–910.

Article  CAS  PubMed  Google Scholar 

Shirani A, Stüve O. Natalizumab for multiple sclerosis: a case in point for the impact of translational neuroimmunology. J Immunol. 2017;198:1381–6.

Article  CAS  PubMed  Google Scholar 

Romme Christensen J, Ratzer R, Börnsen L, Lyksborg M, Garde E, Dyrby TB, et al. Natalizumab in progressive MS: results of an open-label, phase 2A, proof-of-concept trial. Neurology. 2014;82:1499–507.

Article  CAS  PubMed  Google Scholar 

Sellebjerg F, Cadavid D, Steiner D, Villar LM, Reynolds R, Mikol D. Exploring potential mechanisms of action of natalizumab in secondary progressive multiple sclerosis. Ther Adv Neurol Disord. 2016;9:31–43.

Article  CAS  PubMed  PubMed Central  Google Scholar 

von Glehn F, Farias AS, de Oliveira ACP, Damasceno A, Longhini ALF, Oliveira EC, et al. Disappearance of cerebrospinal fluid oligoclonal bands after natalizumab treatment of multiple sclerosis patients. Mult Scler. 2012;18:1038–41.

Article  Google Scholar 

Harrer A, Tumani H, Niendorf S, Lauda F, Geis C, Weishaupt A, et al. Cerebrospinal fluid parameters of B cell-related activity in patients with active disease during natalizumab therapy. Mult Scler J. 2013;19:1209–12.

Article  CAS  Google Scholar 

Rudick RA, Stuart WH, Calabresi PA, Confavreux C, Galetta SL, Radue E-W, et al. Natalizumab plus interferon beta-1a for relapsing multiple sclerosis. N Engl J Med. 2006;354:911–23.

Article  CAS  PubMed  Google Scholar 

Calabresi PA, Giovannoni G, Confavreux C, Galetta SL, Havrdova E, Hutchinson M, et al. The incidence and significance of anti-natalizumab antibodies: results from AFFIRM and SENTINEL. Neurology. 2007;69:1391–403.

Article  CAS  PubMed  Google Scholar 

Kapoor R, Ho P-R, Campbell N, Chang I, Deykin A, Forrestal F, et al. Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension. Lancet Neurol. 2018;17:405–15.

Article  CAS  PubMed  Google Scholar 

Zhovtis Ryerson L, Frohman TC, Foley J, Kister I, Weinstock-Guttman B, Tornatore C, et al. Extended interval dosing of natalizumab in multiple sclerosis. J Neurol Neurosurg Psychiatry. 2016;87:885–9.

Article  CAS  PubMed  Google Scholar 

Perneczky J, Sellner J. Natalizumab extended-interval dosing in multiple sclerosis to mitigate progressive multifocal leukoencephalopathy risk: initial study evidence and real-world experience. J Cent Nerv Syst Dis. 2022;14:11795735221135484.

Article  Google Scholar 

Toorop AA, van Lierop ZY, Gelissen LM, Hoitsma E, Zeinstra EM, van Rooij LC, et al. Prospective trial of natalizumab personalised extended interval dosing by therapeutic drug monitoring in relapsing-remitting multiple sclerosis (NEXT-MS). J Neurol Neurosurg Psychiatry. 2024;95:392–400.

PubMed  Google Scholar 

Wiendl H, Foley J, Defer G, Zhovtis Ryerson L, Cohen JA, Arnold DL, et al. Patient preference for subcutaneous versus intravenous administration with every-6-week natalizumab (Tysabri®) dosing: NOVA phase IIIb extension study (part 2). Neurol Ther. 2024;13:1385–401.

Article  PubMed  PubMed Central  Google Scholar 

Foley JF, Defer G, Ryerson LZ, Cohen JA, Arnold DL, Butzkueven H, et al. Comparison of switching to 6-week dosing of natalizumab versus continuing with 4-week dosing in patients with relapsing-remitting multiple sclerosis (NOVA): a randomised, controlled, open-label, phase 3b trial. Lancet Neurol. 2022;21:608–19.

Article  CAS  PubMed  Google Scholar 

Fox RJ, Cree BAC, De Sèze J, Gold R, Hartung H-P, Jeffery D, et al. MS disease activity in RESTORE: a randomized 24-week natalizumab treatment interruption study. Neurology. 2014;82:1491–8.

Article  CAS  PubMed  PubMed Central  Google Scholar 

Hemmer B, Wiendl H, Roth K, Wessels H, Höfler J, Hornuss C, et al. Efficacy and safety of proposed biosimilar Natalizumab (PB006) in patients with relapsing-remitting multiple sclerosis: the antelope phase 3 randomized clinical trial. JAMA Neurol. 2023;80:298–307.

Article  PubMed  PubMed Central  Google Scholar 

Wessels H, von Richter O, Velinova M, Höfler J, Chamberlain P, Kromminga A, et al. Pharmacokinetic and pharmacodynamic similarity of biosimilar natalizumab (PB006) to its reference medicine: a randomized controlled trial. Expert Opin Biol Ther. 2023;23:1287–97.

Article  CAS  PubMed  Google Scholar 

Selmaj K, Roth K, Höfler J, Vitzithum K, Derlacz R, von Richter O, et al. Introducing the biosimilar paradigm to neurology: the totality of evidence for the first biosimilar natalizumab. BioDrugs. 2024;38:755–67.

Article  PubMed  PubMed Central  Google Scholar 

Cohen JA, Coles AJ, Arnold DL, Confavreux C, Fox EJ, Hartung H-P, et al. Alemtuzumab versus interferon beta 1a as first-line treatment for patients with relapsing-remitting multiple sclerosis: a randomised controlled phase 3 trial. Lancet. 2012;380:1819–28.

Article  CAS  PubMed  Google Scholar 

Coles AJ, Twyman CL, Arnold DL, Cohen JA, Confavreux C, Fox EJ, et al. Alemtuzumab for patients with relapsing multiple sclerosis after disease-modifying therapy: a randomised controlled phase 3 trial. Lancet. 2012;380:1829–39.

Article  CAS  PubMed  Google Scholar 

Baker D, Herrod SS, Alvarez-Gonzalez C, Giovannoni G, Schmierer K. Interpreting lymphocyte reconstitution data from the pivotal phase 3 trials of Alemtuzumab. JAMA Neurol. 2017;74:961–9.

Article  PubMed  PubMed Central  Google Scholar 

Baker D, Herrod SS, Alvarez-Gonzalez C, Zalewski L, Albor C, Schmierer K. Both cladribine and alemtuzumab may effect MS via B-cell depletion. Neurol Neuroimmunol Neuroinflamm. 2017;4:e360.

Article  PubMed  PubMed Central  Google Scholar 

Wiendl H, Bourdette D, Ciccarelli O. Can immune reprogramming with alemtuzumab induce permanent remission in multiple sclerosis? Neurology. 2017;89:1098–100.

Article  PubMed  Google Scholar 

De Mercanti S, Rolla S, Cucci A, Bardina V, Cocco E, Vladic A, et al. Alemtuzumab long-term immunologic effect: Treg suppressor function increases up to 24 months. Neurol Neuroimmunol Neuroinflammation. 2016;3:e194.

Article  Google Scholar 

von Kutzleben S, Pryce G, Giovannoni G, Baker D. Depletion of CD52-positive ce